Literature DB >> 7049073

Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis.

P Patamasucon, G H McCracken.   

Abstract

The pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin were determined in rabbits infected with Escherichia coli K1. After a single intravenous dose of 25 mg/kg, a peak N-formimidoyl thienamycin concentration in cerebrospinal fluid (CSF) of 2.5 micrograms/ml was attained at 45 min. The penetration into CSF was calculated to be 31%. In animals that received continuous intravenous infusions of the drug for 9 h, the mean CSF concentration was 8.2 microgram/ml, and the CSF bactericidal titers against the E. coli K1 strain were from 1:16 to 1:32. This infusion produced a reduction in the numbers of E. coli in the CSF of 4 log10 colony-forming units per ml. N-Formimidoyl thienamycin might prove to be useful for therapy of meningitis caused by E. coli and other susceptible bacteria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049073      PMCID: PMC181901          DOI: 10.1128/AAC.21.3.390

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

2.  Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

3.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

4.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  N-formimidoyl thienamycin (MK0787): in vitro study.

Authors:  S Shadomy; R S May
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

6.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

  8 in total
  9 in total

1.  In vitro and in vivo studies of imipenem-cilastatin alone and in combination with gentamicin against Listeria monocytogenes.

Authors:  K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  Therapeutic effects of imipenem-cilastatin on experimental intrauterine infections in rats.

Authors:  T Hashizume; T Komatsu; Y Okumoto; M Ogashiwa; M Kemi; Z Takase
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.

Authors:  G H McCracken; Y Sakata; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp.

Authors:  S R Preblud; C J Gill; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor.

Authors:  A W Chow; K R Finlay; H G Stiver; C L Carlson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

6.  Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.

Authors:  Y Sakata; G H McCracken; M L Thomas; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Therapy of experimental meningitis due to Salmonella enteritidis.

Authors:  J P Bryan; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.

Authors:  R F Jacobs; G L Kearns; A L Brown; D C Longee
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

9.  Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.

Authors:  Maria Agudelo; Carlos A Rodriguez; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2019-02-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.